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Most of the investigators did not succeed to prove negative effect on bone mineral 
density (BMD) in Rheumatoid Arthritis (RA) patients treated with low dose of 
corticosteroids (CS), but few of them could not confirm this finding. The aim of this study 
was to investigate the effects of low dose CS on BMD of RA premenopausal and 
postmenopausal (PM) patients in Nis region of Serbia. A group of 352 female RA 
patients were categorized according to age in premenopausal and postmenopausal 
group. Each group was subdivided to two sub-groups of premenopausals and PMs (on 
5mg CS; and 6-10±1 mg/daily), as well as according to duration of CS therapy (1 year,  
2-5, 7-11, and over 11 years). BMD was measured by DEXA densitometer in the 
beginning of the trial, 6 months and 1 year after. Control group were healthy persons 
categorized by age and RA premenopausal and PM patients on non steroid anti-
inflammatory drugs (NSAID). BMD of CS (5 mg/day) and NSAID RA premenopausal 
patients is significantly lower (p<0,050) compared to adequate age matched control 
group, with no difference between CS and NSAID treated group after 1 year follow up. 
BMD og CS treated (6-10±1 mg/daily) RA premenopausal patients is lower than NSAID 
treated group (p<0,01). BMD analysis in RA-PM patients on CS 5mg/day gave the same 
results. BMD of these patients is significantly lower than control group (0,994 compared 
to 1,106 g/cm2, p<0,01), but with no difference to NSAID group with BMD of 1,058 
g/cm2. BMD of RA-PM patients treated with 6-10 mg/day is significantly lower compared 
to NSAID treated RA-PM and control (0,992 compared to 1,058 and 1,106 g/cm2). The 
duration of 1 year and 2-6 years CS therapy in RA premenopausal patients gives 
significant difference when compared to controls (p<0,05 and p<0,01 respectively). RA 
PM patients on CS  in duration of 1, 2-6 and 7-11 years did not have  significantly lower 
BMD  compared to NSAID treated RA-PM patients,  but the difference was significant 
when CS treatment last more than 11 years (0,847 compared to 0,980g/cm2, p<0,01). 
Conclusion: Low dose of CS-5mg/day do not have negative effect on BMD of RA 
premenopausal and RA-PM patients. Doses of CS up to 6-10±1mg/day have negative 
effect on BMD of both groups. Despite the multifactorial etiology of generalized 
osteoporosis we can suggest that the duration of CS therapy more than 11 years 
combined with a CS dose up to 10mg/day makes this group of RA-PM at highest risk to 
develop significant generalized osteoporosis. 
